Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2011, Article ID 391576, 9 pages
Review Article

Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer

1Department of Medicine, Section of Endocrinology and Metabolism, Overton Brooks VA Medical Center, Shreveport, LA 71101, USA
2Department of Medicine, Section of Endocrinology and Metabolism, 113 Holland Avenue, Stratton VA Medical Center, Albany, NY 12208, USA

Received 25 January 2011; Revised 4 April 2011; Accepted 6 May 2011

Academic Editor: James L. Gulley

Copyright © 2011 Bhavin R. Shastri and Subhashini Yaturu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Prostate cancer is one of the most common malignancies in men. Charles Huggins and Clarence V. Hodges reported the androgen dependence of prostate cancer in 1941. That led to the utilization of androgen deprivation therapy as an important therapeutic modality to treat prostate cancer. Androgen deprivation therapy has additional systemic effects that include sexual dysfunction, psychological changes and more important are the metabolic changes. Metabolic changes in particular include insulin resistance, increase fat mass and low-density lipoprotein cholesterol, and induce type 2 diabetes. In this review we will focus on the cardiovascular risk associated with androgen deprivation therapy that includes the mechanisms involved.